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Abstract The purpose of this study was to judge the
clinical value of minimally invasive stereotactic puncture
and thrombolysis therapy (MISPTT) for acute intracerebral
hemorrhage (ICH). A randomized control clinical trial was
undertaken. According to the enrollment criteria, 122 acute
ICH cases were analyzed, of which 64 cases received
MISPTT (MISPTT group, MG) and 58 cases received
conventional craniotomy (CC group, CG). The Glasgow
coma scale (GCS) scores, postoperative complications
(PC), and rebleeding incidences were compared. Moreover,
1 year postoperation, the long-term outcomes of patients
with regard to hematoma volume (HV) \50 mL and HV
C50 mL were judged, respectively, by the Glasgow
outcome scale (GOS), Barthel index (BI), modiﬁed Rankin
Scale (mRS), and case fatality (CF). MG patients showed
obvious amelioration in GCS score compared with that of
CG patients. The total incidence of PC in MG decreased
compared with that of CG. The incidences of rebleeding in
MG and CG were 9.4 and 17.2%, respectively (P = 0.243).
There were no obvious differences between the CFs of MG
and CG (17.2 and 25.9%, respectively, P = 0.199). The
GOS, BI, and mRS representing long-term outcome for
both HV\50 mL and HV C50 mL in MG were ameliorated
signiﬁcantly greater than that in CG patients (all P\0.05).
These data suggest that there are advantages with MISPTT
not only in trauma and safety, but the MISPTT group had
fewer complications and a trend toward improved short-
term and long-term outcomes.
Keywords Acute intracerebral hemorrhage  Minimally
invasive stereotactic puncture and thrombolysis therapy 
Conventional craniotomy  Urokinase
Introduction
Spontaneous intracerebral hemorrhage (ICH) comprises
8–30% of all stroke victims, depending on regional and
ethnic differences, and is a devastating form of stroke with
the high mortality twofold to sixfold higher than that for
ischemic stroke [1] and a 1-year survival rate less than 50%
[2]. Hitherto, morbidity and mortality following ICH
remain the highest among all forms of cerebrovascular
diseases, with a 30-day mortality rate of 35–52%, with
50% of the deaths occurring in the ﬁrst 2 days [3–5]. After
initial irreversible tissue injury is suffered near the hem-
orrhage nidus, a progressive cascade of elevated local
pressure, edema, and excitotoxicity cause additional
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DOI 10.1007/s00415-011-5902-7secondary injury to surrounding areas [6–8]. Secondary
brain injury by hematoma often occurs in the days fol-
lowing the initial hemorrhage and is intimately associated
with signiﬁcant neurological deterioration.
Despite being considerably frequent, the treatment of
hematomas within the basal ganglia continues to be a
matter of debate among neurologists and neurosurgeons.
The present powerful evidence provided by the results of
the International Study of the Treatment of Intracranial
Hemorrhage (STICH) corroborates this statement which
has been established previously: there was not signiﬁcant
beneﬁt for conventional aggressive surgical treatment over
conservative medical treatment for the acute care of ICH
[9]. Nevertheless, more than 7,000 patients with ICH in the
United States undergo traditional evacuation procedures
each year [10].
However, various clinical studies testing the hypothesis
that clot burden plays a signiﬁcant role in several forms of
intracranial hemorrhage have been published in recent
years, suggesting that clot reduction plays an important role
in limiting brain edema and additional neuronal injury, as
well as in reducing the severity of neurological deﬁcits
following ICH [11–14]. Because of the lack of validated
therapeutic options for this form of stroke, the role of
minimally invasive surgery (MIS) in the treatment of ICH
has gained importance and several different operational
methods have emerged over the past decade. In this con-
text, our treatment with a stereotactic technique, which we
have termed minimally invasive stereotactic puncture and
thrombolysis therapy (MISPTT), is herewith presented.
MISPTT is a novel operative technique for ICH, which
was developed by Pro Jia in 1997. Although several clin-
ical studies on MISPTT in the acute phase of ICH have
been published during the past decade, the impact of
MISPTT on the short-term and long-term neurological
function of patients who survive the acute phase is less
clear. The purpose of the present study was to investigate
whether the long-term and short-term beneﬁts of MISPTT
are maintained and whether this method improves the
ultimate outcome in these ICH patients. Therefore, we
compared the long-term outcome 1 year after treatment in
a consecutive series of ICH patients treated by MISPTT
with the results achieved in a comparable group of patients
who were treated by conventional craniotomy (CC).
Methods
A randomized control clinical trial was undertaken. All
ICH patients were inhospital patients from 2005–2008
diagnosed with ICH, according to the ICH criteria drafted
by ASA [15]. All cases were monitored in a dedicated
stroke unit. The volume of the ICH in milliliters (mL) was
estimated on the basis of approximate ellipse volume with
the formula A 9 B 9 C/2, where A represents the largest
diameter of the hematoma on axial CT slices in centime-
ters, B the diameter of hematoma perpendicular to A on the
same slice, and C the number of CT slices in which the
hematoma is visible multiplied by the slice thickness in
centimeters [16, 17].
Inclusion and exclusion criteria for patients
Inclusion criteria were as follows: (1) diagnosed as having
spontaneous hemorrhage in the basal ganglion or brain lobe
of the brain by CT scan; (2) hemorrhage volume:
30–100 ml; (3) age range: 40–75 years; (4) muscle strength
of the paralyzed limbs: grades 0–3 on the muscle strength
scale; (5) hemorrhagic duration (from stroke onset to
hospital) within 24 h; and (6) informed consent from
patients and/or their legal representative.
Exclusion criteria were as follows: (1) disturbances of
blood coagulation, e.g., thrombocytopenia, hepatitis; (2)
traumatic intracranial hemorrhage; (3) intracranial or gen-
eral infection; (4) complicated with serious heart, liver,
renal, or lung disease or functional failure; (5) a previous
stroke history with neurological deﬁcits; (6) intracranial
aneurysm or arteriovenous malformation complicated with
hemorrhage; (7) consent form not obtained from the patient
or their legal representative.
There were 122 patients analyzed, of which 64 cases
were treated with MISPTT and 58 cases with CC. There
were no statistically signiﬁcant differences in sex, age,
GCS score, localization of bleeding, hemorrhage volume,
or blood pressure level during hospitalization, duration of
hypertension and the accompanying diseases in the two
groups. Although the accompanying diseases such as dia-
betes, hyperlipidemia, coronary heart disease and cerebral
infarction in the two groups were similar (all P[0.05),
diabetes accounted for 62.5% and 60.3%, respectively, in
MISPTT group and CC group, and was perhaps one
important risk factor for ICH onset (Table 1).
Treatment methods
Minimally invasive stereotactic puncture and thrombolysis
therapy
All operations were performed under local anesthesia and
intravenous sedation unless the patient was already intu-
bated for medical or neurological indications independent
of the procedure. Stereotactic aspiration of the hematomas
was performed in the acute phase between the 6th and the
24th hour after onset of stroke as required in the MISPTT
protocol. First, the target points were deﬁned according to
the CT, and target points were generally chosen in the scan
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123with the largest expansion of the hematoma and special
attention was paid to stay away from important cortex
function areas (Fig. 1). Puncture situs was measured and
marked on the head, again avoiding main blood vessels,
then a puncture needle of suitable length (type YL-1) was
ﬁxed to the operative electric drill. The puncture needle
was entered to the predetermined depth, then the probe
core was removed; the hematoma was withdrawn gently
using a syringe (diluted with saline if blood thickened)
until one-third of hematoma was removed, then a needle-
like hematoma disintegrator was inserted. When no more
blood could be withdrawn, the hematoma cavity was
thoroughly rinsed with saline, until the saline ﬂuid was
clear.
To conﬁrm gross hematoma evacuation, an immediate
postoperative CT scan was taken to assess the puncture
needle placement and residual hematoma volume. If the
placement of puncture needle was at the center of hema-
toma and stable, without rebleeding, a drainage bag con-
nected to the puncture needle was hung 10 cm upon the
head and switched for drainage. Upon rebleeding, 1 ku
reptilase or 1 mg adrenalin should be injected into the
hematoma, drained after 0.5 hour, and rinsed after
6–8 hours. All patients were treated in a dedicated inten-
sive care unit, where subsequent thrombolysis and clot
drainage were performed at the bedside using sterile
techniques. The hematoma was continuously liqueﬁed by
liquefacient (containing 20,000–40,000 U urokinase/
2–3 mL saline solution) for 2–4 days (3–5 times/day).On
the 1st, 3rd, 5th, and 7th day of postoperation, patients
were re-examined using CT. For hematomas that are dif-
ﬁcult to liquefy, it should be liqueﬁed as far as possible at
ﬁrst, followed by repeated, gentle aspiration using an agi-
tation maneuver of the liquefacient to achieve vacuity. For
hematomas affecting one lateral cerebral ventricle, then
only that hematoma cavity should be perforated, but for
patients with a hematoma affecting both lateral cerebral
ventricles and the casting mould, the hematoma cavity and
the contralateral cerebral ventricle should be perforated
simultaneously.
In addition, for those patients with a hematoma breaking
into the lateral cerebral ventricle, lumbar puncture could be
Table 1 The baseline
characteristics of patients
Group MISPTT patients CC patients P value
Number of patients 64 58
Gender (m:f) 41:23 38:20 0.866
Mean age (years) 58.7 ± 9.0 57.6 ± 8.6 0.483





Hematoma volume (n/%) 0.987
30–49 (mL) 27/42.2 22/37.9
50–79 (mL) 23/35.9 21/36.2
80–100 (mL) 14/21.9 15/25.9
Direction of the hematoma (n/%) 0.468
Left-sided 34/53.3 27/51.3
Right-sided 30/46.7 31/48.7
Location of the hematoma (n/%) 0.344
Basal ganglia 48/53.3 39/50.0
Thalamus 16/17.8 19/24.4
Mean BP
SBP 174.3 ± 14.1 172.2 ± 11.0 0.361
DBP 96.7 ± 9.7 98.8 ± 9.4 0.255
Duration of BP (years) 7.1 ± 1.9 7.4 ± 2.0 0.312
Accompanied disease (n/%)
Diabetes 40/62.5 35/60.3 0.807
Hyperlipidemia 27/42.2 22/37.9 0.632
Coronary heart disease 20/31.3 21/36.2 0.563
Cerebral infarction 14/21.9 15/25.9 0.605
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123performed to repeatedly replace cerebral spinal ﬂuid using
NS until the color is pale for 4–5 days (once/day). When
the hematoma was cleared or the remaining volume was
less than 10 mL, the general condition of the patient was
stable and intracranial pressure was normal; the puncture
needle was removed, if no intracranial hypertension
developed after occluding the drainage tube for 24 hours.
The puncture needle was removed at the bedside under
sterile conditions, and a single suture was placed at its exit
site and covered with an occlusive dressing. In addition, all
patients received optimal medical treatment.
Conventional craniotomy
Between 6 and 24 hours after onset, clearance of the
hematoma by traditional craniotomy with large bone ﬂap
removal was performed in the Department of Neurosur-
gery. The medical treatment was routinely performed.
Follow-up and outcome assessment
Evaluation of all 122 patients followed identical criteria.
Initial assessment included baseline characteristics (age,
gender, HV, etc). The pretreatment clinical state of this
cohort was assessed according to the GCS. All 122 cases in
the two groups could be matched with regard to baseline
characteristics. The posttreatment clinical state of the
patients was assessed according to the GSC score,
incidence of complications, and recurrence of bleeding
after surgery. Outcome 1 year after stroke was the major
endpoint. Four outcome parameters commonly used to
assess outcome were employed to study the full impact of
hemorrhagic stroke on long-term follow-up. Total case
fatality was deﬁned 1 year after stroke. According to the
Glasgow outcome scale (GOS), clinical outcomes were
graded, ranging from good recovery (GOS 5) to dead (GOS
1). The performance and functional status of the patients in
activities of daily living (ADL) were measured with the
Barthel index (BI 0–100). Disability was assessed using the
modiﬁed Rankin scale (mRS 0–5). The data of all four
outcome parameters for the two treatment groups were
analyzed and compared.
Statistics
Categorical variables were analyzed using the v
2 test or
Fisher’s exact test for small samples. Measurement data
were analyzed using t tests. All recorded data were input
using Epi Info software and statistically analyzed using
SPSS 11.5 statistical software. For all analyses, P\0.05
was considered to be statistically signiﬁcant.
Results
Comparison of consciousness level after surgery, GCS
score, and the incidence of complications
between the two groups
The GCS scores between the two groups prior to the
operation were not signiﬁcantly different (P = 0.998). The
total incidence of complication in the MISPTT group was
lower than that of the CC group (P = 0.000). Pulmonary
infection, digestive tract hemorrhage, and epilepsy in the
MISPTT group were all lower than that observed in the CC
group (P = 0.047, P = 0.016, and P = 0.010, respec-
tively). The incidence of bleeding recurrence was not sig-
niﬁcantly different between the two groups (P = 0.199)
(Table 2). Typical examples from the study are shown; for
example, CT scans of one coma patient (GCS score 5) with
a huge hematoma ([70 mL) are shown in Fig. 2. There
were obvious difference in the HV and edema of sur-
rounding brain before MISPTT with a GCS score of 5 and
2 weeks after MISPTT with a GCS score of 14. The patient
was self-sufﬁcient 1 year after on-set (Fig. 2).
Comparison of long-term outcome and total case
fatality of the two groups 1 year after stroke
There were no sharp differences in case fatality between
the MISPTT group and the CC group 1 year after stroke
Fig. 1 The slice of the largest hematoma area and puncture point in
the CT are illustrated. AB median sagittal line, CD precoronal line, EF
lateral sagittal line, P puncture point of hematoma, H center of
hematoma, G puncture point of lateral cerebral ventricle, PH puncture
depth, L lateral cerebral ventricle
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123(17.2 and 25.9%, respectively, P = 0.243); however, on
the whole, the results showed that the survival in the
MISPTT group was signiﬁcantly better than that of the CC
group. There were 27 cases with a HV \50 mL in the
MISPTT group and there were no deaths 1 year postop-
eration, and 22 cases with a HV\50 mL in the CC group,
of whom 2 had died within 1 year postoperation. Three
parameters representing long-term outcome, the GOS
(4.4 ± 0.6), BI (82.6 ± 9.5), and mRS (1.8 ± 1.0) in the
MISPTT group with a HV \50 mL had signiﬁcantly
ameliorated compared to those in the CG group (GOS
3.4 ± 1.1, BI 73.0 ± 14.6, and mRS 2.7 ± 1.3, respec-
tively) (P = 0.000, P = 0.009, and P = 0.009, respec-
tively). There were 37 cases with a HV C50 mL in the
MISPTT group, of whom 11 patients had died 1 year
postoperation, while there were 36 cases with a HV
C50 mL in the CC group and 13 patients had died 1 year
postoperation. The GOS (3.3 ± 1.6), BI (73.3 ± 15.6), and
mRS (2.2 ± 1.2) in the MISPTT group with a HV C50 mL
had signiﬁcantly ameliorated compared to those in the CG
Table 2 Consciousness level
after surgery, GCS score, and
incidence of complications
Group MISPTT patients CC patients P value
Number of patients 64 58
GCS score
Before operation 8.7 ± 1.9 8.4 ± 2.2 0.445
After operation 11.0 ± 1.2 8.1 ± 1.0 0.000
Incidence of complication (n/%) 20/31.3 46/79.3 0.000
Pulmonary infection 6/9.4 13/22.4 0.047
Digestive tract hemorrhage 10/15.6 20/34.5 0.016
Epilepsy 4/6.3 13/22.4 0.010
Bleeding recurrence (n/%) 6/9.4 10/17.2 0.199
Fig. 2 CT scans of a patient in a coma (GCS score 5) with a large
hematoma ([70 mL) before MISPTT (top), and CT scans of the same
patient during consciousness (GCS score 14) 2 weeks after MISPTT
(bottom). These scans demonstrate the size of the hematoma on serial
axial CT images. CT scans 2 weeks after MISPTT showed obvious
amelioration in hematoma volume and edema in the surrounding
brain compared with that prior to MISPTT. The patient was able to
completely return to a normal lie 1 year after on-set
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3.0 ± 1.6, respectively) (P = 0.040, P = 0.042, and
P = 0.033, respectively). The results are shown in Table 3.
Discussion
The mass effect of a hematoma can lead to the brain
damage, including intracranial hypertension or cerebral
hernia [18]. There is, however, some evidence that the
mass effect caused by a HV (\60 mL) was not the domi-
nant injury mechanism, whereas the toxic substances
released from the hematoma were the most important
factor in the pathological mechanism of the cerebral
hemorrhage [19–21]. It was reported that elevated levels of
glutamate were found in the perihematomal region after
ICH and these levels decreased after hematoma drainage.
Conversely, ischemic LPRs were not found in perihemat-
omal regions and were unchanged after hematoma drain-
age. These data suggest that excitotoxicity related to
glutamate may have an important impact on secondary
injury. The data failed to support the role of ischemia in
secondary perihematomal damage [6].
Thus, effective removal of the hematoma during the
acute phase is a crucial principle in the treatment of ICH in
order to save lives and improve long-term quality of life.
CC by removing a bone ﬂap is a classical technique for the
treatment of ICH, which is characterized by good visuali-
zation, complete clearance of the hematoma, easy hemo-
stasia, and complete reduction of pressure, but also has
some shortcomings such as length of operation, severe brain
damage due to manipulation of the brain during the oper-
ation, damage of brain tissue around the hematoma by
electrocoagulation, re-bleeding readily, pathophysiological
changes postoperation (e.g., disturbance of water and
electrolyte balances, ﬂuctuation of blood sugar, instability
of life signs), which result in severe impairment of neuro-
logical function, multiple complications, higher invalidism
rates and fatality rates. With regard to basal ganglia hem-
orrhages, comparing the outcome of patients treated surgi-
cally with that of patients managed conservatively, many
earlier and current publications showed no beneﬁt from
conventional surgery [9, 10, 22–25]. Only a few reports
have demonstrated a trend towards better outcomes with
conventional surgery [26–28]. While analyzing the given
data, it becomes obvious that the major drawback in all
these studies is the heterogeneity of the ICH patient groups
with regard to their preoperative neurological status due to
the very different degrees of neurological impairment and
no uniform consciousness levels, applying different surgical
approaches, and different intervals with regard to the onset
of the hemorrhagic stroke. Thus, it is an essential issue to
select appropriate patients and a homogenous group to
determine whether patients truly beneﬁt from the neuro-
surgical stereotactic evacuation of the hematomas in the
acute phase. In many recent studies, the minimally invasive
methods have shown to be highly efﬁcient with little risk of
re-bleeding and better short-term outcomes [29–31]. Pres-
ently, some clinicians are exploring new methods to elevate
curative effect of minimally invasive operation techniques.
A study by Marquardt and coworkers [32] focused on the
use of a novel multiple target aspiration technique in 64
patients to aspirate a ‘‘sufﬁcient proportion’’ of the hema-
toma with minimal risk for the patient. More than 80% of
the hematoma volume was successfully aspirated in 73.4%
of the patients with only one episode of re-bleeding. Montes
et al. [33] showed that CT-guided thrombolysis and aspi-
ration was safe and effective in the reduction of ICH vol-
ume. In the meantime, they proposed further studies were
needed to assess optimal thrombolytic dosage, including
controlled comparisons of mortality, disability outcome,
time until convalescence, and cost of care in treated and
untreated patients.
MISPTT is a new and novel operative technique that is
obviously different from other types of minimally invasive
operations in design principle, which was developed by Pro
Table 3 Outcome 1 year after
stroke
GOS Glasgow outcome scale,
mRS modiﬁed Rankin Scale, BI
Barthel index, HV Hematoma
volume
Group MISPTT patients CC patients P value
Number of patients 64 58
Case fatality (n/%) 11/17.2 15/25.9 0.243
GOS
HV\50 mL 4.4 ± 0.6 (27 cases) 3.4 ± 1.1 (22 cases) 0.000
HV C 50 mL 3.3 ± 1.6 (37 cases) 2.5 ± 1.5 (36 cases) 0.040
BI
HV\50 mL 82.6 ± 9.5 (27 cases) 73.0 ± 14.6 (20 cases) 0.009
HV C 50 mL 73.3 ± 15.6 (26 cases) 62.2 ± 21.5 (23 cases) 0.042
mRS
HV\50 mL 1.8 ± 1.0 (27 cases) 2.7 ± 1.3 (20 cases) 0.009
HV C 50 mL 2.2 ± 1.2 (26 cases) 3.0 ± 1.6 (23 cases) 0.033
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123Jia in 1997 with a distinctive thrombolysis installation, and
highly safe and efﬁcient function for dissolving and
draining coagulated blood. This treatment had been widely
applied in China. According to some studies in the past, it
was presented that MISPTT in acute ICH efﬁciently
cleared the hematoma, relieved hydrocephalus, reduced
intracranial hypertension, and relieved the cytotoxicity of
blood thrombin. Furthermore, the washing liquor decreased
the levels of cytotoxic substances. In subacute hemorrhage,
MISPTT reduced the neurotoxicity of the hemoglobin and
its decomposition products. This technique is characterized
by its simplicity and is not limited by equipment. Punc-
turing the brain in MISPTT does little harm to the brain and
accelerates recovery of cerebral function, while the lique-
faction technique contributes to liquefying the blood
coagulum—all helping to shorten the course of disease. In
the operations performed, patients were only treated with a
3 mm needle (diameter). Because there is no gap between
the needle and skull, the incidence of infection is reduced.
Furthermore, it is not necessary to open the skull and use
general anesthesia; thus, this procedure is more economical
than other operations. The Chinese National Research and
Extension Community of the Minimally Invasive Opera-
tion suggested that MISPTT is suitable for cases having a
hemorrhage volume[30 mL in the basal ganglia and fur-
ther standardized the operation indication, operation pro-
cedure, and the methods to apply the hematoma
liquefacient, according to the random sampling of The
Ministry of Public Health.
Although there are many studies investigating the min-
imally invasive operation indication for ICH, few specially
concerned the indication for the MISPTT. Furthermore,
most of these investigations lacked control groups with
uniform baseline characteristics prior to operation, did not
analyze the correlation factors (e.g., GCS score, hematoma
volume, hematoma location, duration of BP and accom-
panied diseases), and did not observe the long-term out-
come for survival. In our study, the above shortcomings
were overcome by the inclusion of many factors, e.g.,
preoperative neurological status, surgical approach, patient
selection, GCS score, incidence of complications, reblee-
ding after surgery, and long-term outcome 1 year after
onset. In addition, accompanying diseases in the two
groups of ICH patients were observed, such as diabetes,
hyperlipidemia, coronary heart disease and cerebral
infarction. There were no statistically signiﬁcant differ-
ences between the two groups (all P[0.05), but it was
noticed that diabetes accounted for 62.5% and 60.3%,
respectively, in MG and CG, which indicated that diabetes
was perhaps one important risk factor for ICH onset (Table
1). The results showed that the level of consciousness and
GCS in MISPTT were better than that of the CC group. Of
the 13 patients with GCS scores of 4–5 in the two groups,
11 patients died (84.6%); the two survivors were treated
with MISPTT (Table 1, one case referring to Fig. 2). The
incidence of complications (e.g., pulmonary infection,
hemorrhage of the digestive tract, and epilepsy) in MISPTT
was obviously reduced compare to the CC group. There
were no cases of intracranial infection in either the MIS-
PTT or the craniotomy group. The statistical analysis did
not show a signiﬁcant difference on the rebleeding inci-
dence in the two groups (9.4 and 17.2%, respectively,
P = 0.199). There were no obvious differences between
the case fatalities in the MISPTT group and the CC group
(17.2 and 25.9%, respectively, P = 0.243). The long-term
outcome in the MISPTT group surpassed that of the CC
group, with respect to GOS, mRS, and BI (all P = 0.000).
Currently, the thrombolysis methods have only been
partly explored. We used UK as thrombolysis method in
our MISPTT study. In another cohort of ICH patients
treated using FAST, volumetric analysis of ICH and
perihematomal edema seemed to suggest that local use of
rtPA for thrombolysis, which differed from the UK used in
our MISPTT study, does not exacerbate brain edema for-
mation. Furthermore, there seems to be a strong association
between reduction of the ICH volume and reduction of
edema volume, as would be expected following the concept
of ‘‘hemotoxicity’’ postulated by some investigators [34].
These above results indicate that for the ICH patient
meeting MISPTT operation requirements, it is unsuitable to
choose CC. However, if the patient has a huge hemorrhage
volume, is rapidly deteriorating, or is in the early state of
cerebral hernia, then a craniotomy should be selected to
reduce cerebral pressure. In addition, another study [33]
pointed out that although MIS on patients with cerebral
hernia may not result in a good curative effect, the hema-
toma volume can be partially decrease and the intracranial
pressure can be rapidly reduce, thus, gaining time for
craniotomy. Of course, CC is occasionally superior in the
treatment of ICH with bulk volume. Murthy et al. [35]
combined decompressive craniectomy and hematoma
clearance to cure 12 patients with hemorrhage volumes
[60 mL in the right hemisphere. As a result, 11 survivors
were able to leave the hospital (92% survival rate), while in
6 cases, the survivors recovered well.
Conclusion
Larger randomized trials proving the increased beneﬁts of
MISPTT treatment over traditional craniotomy or purely
medical management are currently in process. However,
our study and some other treatment trials regarding this
treatment modality have reported optimistic results,
showing superiority of MMISPTT over CC or PMT. Sev-
eral methodological issues surrounding this form of
J Neurol (2011) 258:661–669 667
123treatment remain to be resolved, including comparison of
the relative efﬁcacies of various mechanisms of clot
thrombolysis and drainage. If successful, MISPTT for ICH
may perhaps become an important tool in the growing
treatment armamentarium for ICH and the potential for a
disease modifying impact in these ICH patients. It is our
hope that this ongoing study will bring us closer to other
randomized tests regarding more relevant factors with
MISPTT as an alternative treatment for ICH. Objectively,
MISPTT is currently limited in its ability to achieve
hemostasis and completely evacuate the hematoma. Proper
selection of the ICH patient group to receive this type of
therapy may hold the key to these advances.
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